Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021-Reference-Cited by-同舟云学术

Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021

Published:2021-09-30 Issue:39 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Martínez-Baz Iván¹²³^ORCID,Trobajo-Sanmartín Camino⁴¹^ORCID,Miqueleiz Ana⁴¹,Guevara Marcela¹²³^ORCID,Fernández-Huerta Miguel⁴¹,Burgui Cristina¹²³,Casado Itziar¹²³^ORCID,Portillo María Eugenia⁴¹,Navascués Ana⁴¹,Ezpeleta Carmen⁴¹,Castilla Jesús¹²³^ORCID,

Affiliation:

1. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain

2. CIBER Epidemiología y Salud Pública (CIBERESP), Spain

3. Instituto de Salud Pública de Navarra, Pamplona, Spain

4. Clinical Microbiology Department, Complejo Hospitalario de Navarra, Pamplona, Spain

Abstract

COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference21 articles.

1. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.;Polack;N Engl J Med,2020

2. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.;Voysey;Lancet,2021

3. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.;Baden;N Engl J Med,2021

4. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19.;Sadoff;N Engl J Med,2021

5. Ministerio de Sanidad. Estrategia de detección precoz, vigilancia y control de COVID-19. [Strategy for early detection, surveillance and COVID-19 control]. Madrid: Ministerio de Sanidad; 2021. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Submicro-Optical Spectroscopy Bioassay System for COVID-19 Neutralizing Antibody Immunity Response;IEEE Sensors Journal;2024-09-01

2. Relative and Temporal Efficacy of the First and Second Covid 19 Booster Vaccine (3rd And 4th Dose) to Prevent Symptomatic Infection from December 2021 to October 2023 in a General Medicine Office in Toledo (Spain);Journal of Health Care and Research;2024-05-21

3. Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework;Infectious Diseases and Therapy;2024-03-18

4. Effectiveness of 4th doses of bivalent mRNA vaccine in reinfections from October 2022 to October 2023 in a general medicine office in Toledo (Spain);Archives of Community Medicine and Public Health;2024-03-14

5. COVID-19, social determinants of transmission in the home. A population-based study;European Journal of Public Health;2024-02-23